Rhabdomyosarcoma Global Market Report 2025

The rhabdomyosarcoma market size has grown rapidly in recent years. It will grow from $1.23 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historic period can be attributed to factors such as increased funding for cancer research, the availability of targeted therapies, advancements in surgical techniques and approaches, growth in pediatric oncology programs, and improvements in healthcare policies.

The rhabdomyosarcoma market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth during the forecast period can be attributed to enhanced understanding of cancer biology, improvement in prognostic tools, growing focus on early detection and prevention, expansion of global oncology networks, and multi-disciplinary treatment approaches. Major trends in the forecast period include advancements in immunotherapy, liquid biopsy for early detection, organoids for drug screening, enhanced radiotherapy techniques and regenerative medicine.

The rising investments in oncology research and medicine are expected to drive the growth of the rhabdomyosarcoma market. These investments refer to the financial contributions made by governments, pharmaceutical companies, research institutions, and private investors aimed at advancing the understanding, prevention, diagnosis, and treatment of cancer. The increasing investments are driven by the growing global cancer burden, advancements in precision medicine, the demand for innovative therapies, the expansion of clinical trials, and government and private funding initiatives. These investments help advance rhabdomyosarcoma treatments by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving pediatric cancer care infrastructure, and supporting research to better understand the disease's biology and progression. For example, in May 2024, IQVIA, an India-based analytics company, reported that global spending on cancer medicines reached $223 billion in 2023, marking a $25 billion increase from 2022. This spending is expected to rise to $409 billion by 2028, further driving growth in the rhabdomyosarcoma market.

Improvements in healthcare facilities are also expected to drive the growth of the rhabdomyosarcoma market. Healthcare facilities, such as hospitals, clinics, and diagnostic centers, offer essential medical care and support to patients. The enhancement of these facilities is driven by factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Rhabdomyosarcoma drives advancements in healthcare facilities by necessitating specialized diagnostic tools, innovative treatment protocols, and multidisciplinary care approaches, which ultimately foster improvements in oncology research, pediatric cancer management, and the development of targeted therapies. For example, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, marking a 0.591% increase from the previous year, when there were 6,093 hospitals. This growth in healthcare facilities contributes to the expansion of the rhabdomyosarcoma market.

Regulatory approvals with rare pediatric disease designation (RPDD) are also enhancing the market presence. RPDD is a special status granted by regulatory agencies to encourage the development of treatments for serious, life-threatening rare diseases affecting children. For instance, in January 2022, Immix Biopharma, Inc., a US-based biotech company, received RPDD from the FDA for its drug IMX-110, designed to treat rhabdomyosarcoma in children. IMX-110 is the first clinical-stage product in the SMARxT Tissue-Specific Platform. It contains a poly-kinase inhibitor and apoptosis inducer that targets the tumor microenvironment. This drug works by accumulating at therapeutic sites more effectively than conventional drugs, attacking cancer cells, cancer-associated fibroblasts, and tumor-associated macrophages, which ultimately leads to tumor apoptosis. The RPDD approval helps expand the market presence for this treatment and solidifies its position in treating rhabdomyosarcoma.

Major players in the rhabdomyosarcoma market are Pfizer Inc., Merck & Co Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., GE HealthCare Technologies Inc., Eisai Co Ltd., Ipsen S.A., Elekta AB, Acrivon Therapeutics Inc., Larvol Inc., Oasmia Pharmaceutical AB, Immix Biopharma Inc., Cellectar Biosciences Inc., Lantern Pharma Inc., ApconiX Ltd., Oncoheroes Biosciences Inc.

North America was the largest region in the rhabdomyosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhabdomyosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Rhabdomyosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rhabdomyosarcoma refers to a type of cancer that arises from muscle tissue, primarily affecting children and young adults. Rhabdomyosarcoma is useful to identify and treat early, as early detection improves the chances of successful treatment and survival.

The main types of rhabdomyosarcoma are embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, and other types. Embryonal rhabdomyosarcoma (ERMS) is a common type of rhabdomyosarcoma that typically affects younger children and occurs in soft tissues such as muscles. The various treatments, include surgery, radiation therapy, chemotherapy, and stem cell therapy, and various diagnoses such as imaging tests, X-rays, computed tomography scans, magnetic resonance imaging scans, positron emission tomography scans, bone scans, biopsies, needle biopsies, and surgical biopsies.

The rhabdomyosarcoma research report is one of a series of new reports that provide rhabdomyosarcoma market statistics, including rhabdomyosarcoma industry global market size, regional shares, competitors with a rhabdomyosarcoma market share, detailed rhabdomyosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the rhabdomyosarcoma industry. This rhabdomyosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rhabdomyosarcoma market consists of revenues earned by entities by providing services such as genetic testing, pain management, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rhabdomyosarcoma market also includes sales of chemotherapy agents, and combination regimes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.